Profile of maraviroc: a CCR5 antagonist in the management of treatment-experienced HIV patients
Thore LorenzenIFI Institute for Interdisciplinary Medicine, Hamburg, GermanyAbstract: Maraviroc is the first and, so far, the only licensed representative of the class of chemokine receptor type 5 (CCR5) inhibitors used for the treatment of human immunodeficiency virus (HIV) infection. Its safety an...
Guardado en:
Autor principal: | Thore Lorenzen |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://doaj.org/article/905b7ba498134757a0babd806097faed |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Optimizing management of treatment-naïve and treatment-experienced HIV+ patients: the role of maraviroc
por: Eva Poveda, et al.
Publicado: (2010) -
Profile of darunavir in the management of treatment-experienced HIV patients
por: Cameron Wolfe, et al.
Publicado: (2009) -
The role of etravirine in the management of treatment-experienced pediatric patients with HIV
por: Osterholzer D
Publicado: (2013) -
Role of etravirine in the management of treatment-experienced patients with human immunodeficiency virus type 1
por: Rolando M Viani
Publicado: (2010) -
CCR5 Receptor Occupancy Analysis Reveals Increased Peripheral Blood CCR5+CD4+ T Cells Following Treatment With the Anti-CCR5 Antibody Leronlimab
por: Xiao L. Chang, et al.
Publicado: (2021)